ABIVAX is trading at €83.25, up 6.80%, amid a biotech-sector rally.
- The XBI was up 2.10% during the regular session, with sector sentiment supported by M&A activity and clinical-trial news.
- No confirmed ABIVAX-specific announcement was identified as explaining the October 20 move.
- Reports about obefazimod data and takeover speculation provide background but do not establish a cause for this price change.